Viehbacher’s Biogen strategy 

Christopher Viehbacher has a tiger by the tail, and the entire biotech community is watching to see what he does with it.

Viehbacher, named president and CEO of Biogen Inc. (NASDAQ:BIIB) in November, sat down with BioCentury in Washington this week to talk about his vision for the company’s future. He acknowledged challenges, starting with declining revenues and a high cost base, stressed the importance and complexities of executing successful launches for Leqembi lecanemab-irmb for Alzheimer’s disease and zuranolone for major depressive disorder, and hinted at future directions. ...